retatrutide contraindications side effects: What to know Who Should Not Take Retatrutide?

Lancet 2021 Phase 2 (monotherapy) Lau et al., n=706, 26 weeks

Novo Nordisks new oral GLP-1, Wegovy pill, is a once-daily pill offering comparable weight-loss results (an average of 13.6% of your body weight) to injectable Wegovy.^ ^Eligible patients lost an average of 13.6% of their body weight in a 64-week clinical trial evaluating 25 mg oral semaglutide compared to those on 2.4 mg injectable semaglutide who lost an average of 14.9% of their body weight in a 68-week clinical trial

Collectively, these results highlight the role of vagal afferents in mediating the metabolic and appetite-regulating effects of peripheral GLP-1, thereby linking gut-derived signals to central regulatory circuits

Take Our Poll: Would you ever use a weight loss drug like Ozempic

Nommsen-Rivers LA

It is often discussed for its potential role in tissue repair pathways, collagen activity, blood flow regulation, and recovery support